A case of non-SIADH-induced hyponatremia in depression after treatment with reboxetine.
Hyponatremia is a well-known side effect of antidepressant treatment with serotonin reuptake inhibitors (SSRI) or combined serotonin and noradrenaline reuptake inhibitors (SNRI), and is linked to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in most cases. In contrast, only very few data are available on hyponatremia following treatment with selective noradrenaline reuptake inhibitors (NaRI). In this report, we describe the case of a patient who developed severe hyponatremia after treatment with reboxetine. However, extensive laboratory testing did not reveal inappropriate secretion of ADH, suggesting that SIADH did not account for hyponatremia in our case. Proposing further examination of the underlying pathomechanism of hyponatremia as a side effect of NaRIs, we discuss the importance of careful monitoring of serum sodium levels in patients treated with NaRIs.
Koelkebeck
Katja
K
University of Muenster, Department of Psychiatry, Muenster, Germany. katja.koelkebeck@ukmuenster.de
Domschke
Katharina
K
Zwanzger
Peter
P
Hetzel
Guenter
G
Lang
Detlef
D
Arolt
Volker
V
D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D007177:Inappropriate ADH Syndrome / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D009025:Morpholines / Q000009:adverse effects* / Q000627:therapeutic use; D000077593:Reboxetine; D012008:Recurrence; D012964:Sodium / Q000097:blood
D000928:Antidepressive Agents; D009025:Morpholines; D000077593:Reboxetine; D012964:Sodium